Subscribe
shutterstock_1246881214_piotr_swat
Piotr Swat / Shutterstock.com
11 February 2021Big PharmaAlex Baldwin

Celgene sues Dr Reddy’s over Pomalyst generic

Celgene has filed a lawsuit against Indian drugs manufacturer Dr Reddy’s Laboratories (DRL) to halt its plan to produce and market generic versions of Pomalyst (pomalidomide)—Celgene’s multiple myeloma treatment.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Lawsuit against Celgene, BMS and others moves forward
25 April 2023   New Jersey judge denies motion to stay antitrust action regarding blockbuster cancer drug | Defendants had argued litigation would be unnecessary and costly.
Big Pharma
Dr Reddy’s to receive $72m in Suboxone settlement
27 June 2022   India-based Dr Reddy’s has ended its litigation with Indivior and Aquestive Therapeutics over a generic version of opioid addiction treatment Suboxone sublingual film.
Americas
Celgene, Dr Reddy's abandon cancer drug patent dispute
1 February 2022   Bristol-Myers Squibb subsidiary, Celgene has settled its lawsuit against India-based drug maker Dr Reddy's over a generic version of the blockbuster cancer treatment, Pomalyst.


Editor's picks

Smart ringleader: Could Ōura’s market dominance be under threat?
Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025

Editor's picks

Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025
Europe
Sandoz blocked by UK court from seeking Xarelto profits
2 September 2025
Europe
UPC sees rising small molecule litigation with Pfizer in the hot seat
29 August 2025
Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025
Europe
Four firms reach highest tier in WIPR’s 2025 Global Trade Secrets Rankings
18 August 2025
Americas
Latham steps into dispute over $6bn treatment, replacing Kirkland
13 August 2025

More on this story

Americas
Lawsuit against Celgene, BMS and others moves forward
25 April 2023   New Jersey judge denies motion to stay antitrust action regarding blockbuster cancer drug | Defendants had argued litigation would be unnecessary and costly.
Big Pharma
Dr Reddy’s to receive $72m in Suboxone settlement
27 June 2022   India-based Dr Reddy’s has ended its litigation with Indivior and Aquestive Therapeutics over a generic version of opioid addiction treatment Suboxone sublingual film.
Americas
Celgene, Dr Reddy's abandon cancer drug patent dispute
1 February 2022   Bristol-Myers Squibb subsidiary, Celgene has settled its lawsuit against India-based drug maker Dr Reddy's over a generic version of the blockbuster cancer treatment, Pomalyst.

More on this story

Americas
Lawsuit against Celgene, BMS and others moves forward
25 April 2023   New Jersey judge denies motion to stay antitrust action regarding blockbuster cancer drug | Defendants had argued litigation would be unnecessary and costly.
Big Pharma
Dr Reddy’s to receive $72m in Suboxone settlement
27 June 2022   India-based Dr Reddy’s has ended its litigation with Indivior and Aquestive Therapeutics over a generic version of opioid addiction treatment Suboxone sublingual film.
Americas
Celgene, Dr Reddy's abandon cancer drug patent dispute
1 February 2022   Bristol-Myers Squibb subsidiary, Celgene has settled its lawsuit against India-based drug maker Dr Reddy's over a generic version of the blockbuster cancer treatment, Pomalyst.

More features

GSK escalates mRNA COVID-19 vaccine dispute
Smart ringleader: Could Ōura’s market dominance be under threat?
The flaw that landed Sanofi a win in the rare disease space
Roche resolves cancer test dispute with Stanford affiliated startup
Why Masimo’s ‘rare’ move pushes Apple case into uncharted territory
UK firm expands in Germany with more litigation hires
Sandoz blocked by UK court from seeking Xarelto profits
An update on patenting in Ukraine, Russia and Eurasia